HEMOGENYX PHARMPLC Valuation
| 5HU Stock | EUR 4.14 0.62 13.03% |
At this time, the firm appears to be overvalued. HEMOGENYX PHARMPLC retains a regular Real Value of €3.04 per share. The prevalent price of the firm is €4.14. Our model calculates the value of HEMOGENYX PHARMPLC from examining the firm fundamentals such as Return On Asset of -0.18, return on equity of -0.32, and Shares Owned By Insiders of 15.17 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that HEMOGENYX PHARMPLC's price fluctuation is out of control at this time. Calculation of the real value of HEMOGENYX PHARMPLC is based on 3 months time horizon. Increasing HEMOGENYX PHARMPLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the HEMOGENYX stock is determined by what a typical buyer is willing to pay for full or partial control of HEMOGENYX PHARMPLC LS 01. Since HEMOGENYX PHARMPLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HEMOGENYX Stock. However, HEMOGENYX PHARMPLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.14 | Real 3.04 | Hype 4.14 |
The real value of HEMOGENYX Stock, also known as its intrinsic value, is the underlying worth of HEMOGENYX PHARMPLC Company, which is reflected in its stock price. It is based on HEMOGENYX PHARMPLC's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HEMOGENYX PHARMPLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HEMOGENYX PHARMPLC LS 01 helps investors to forecast how HEMOGENYX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HEMOGENYX PHARMPLC more accurately as focusing exclusively on HEMOGENYX PHARMPLC's fundamentals will not take into account other important factors: HEMOGENYX PHARMPLC Total Value Analysis
HEMOGENYX PHARMPLC LS 01 is presently estimated to have takeover price of 0 with market capitalization of 24.89 M, debt of 1.63 M, and cash on hands of 1.81 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the HEMOGENYX PHARMPLC fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 24.89 M | 1.63 M | 1.81 M |
HEMOGENYX PHARMPLC Asset Utilization
One of the ways to look at asset utilization of HEMOGENYX is to check how much profit was generated for every dollar of assets it reports. HEMOGENYX PHARMPLC retains a negative application of resources of -0.18 (percent), losing €0.001771 for each euro of resources held by the firm. Unproductive asset utilization attests that the company is being less capable with each euro of resources it retains. Simply put, asset utilization of HEMOGENYX PHARMPLC LS 01 shows how inefficient it operates for each euro spent on its resources.HEMOGENYX PHARMPLC Ownership Allocation
HEMOGENYX PHARMPLC LS 01 has a total of 979.75 Million outstanding shares. HEMOGENYX PHARMPLC retains 15.17 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.HEMOGENYX PHARMPLC Profitability Analysis
Net Loss for the year was (2.08 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates HEMOGENYX PHARMPLC's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in HEMOGENYX PHARMPLC and how it compares across the competition.
About HEMOGENYX PHARMPLC Valuation
The stock valuation mechanism determines HEMOGENYX PHARMPLC's current worth on a weekly basis. Our valuation model uses a comparative analysis of HEMOGENYX PHARMPLC. We calculate exposure to HEMOGENYX PHARMPLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HEMOGENYX PHARMPLC's related companies.Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was incorporated in 2013 and is headquartered in London, the United Kingdom. HEMOGENYX PHARM is traded on Frankfurt Stock Exchange in Germany.
8 Steps to conduct HEMOGENYX PHARMPLC's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates HEMOGENYX PHARMPLC's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct HEMOGENYX PHARMPLC's valuation analysis, follow these 8 steps:- Gather financial information: Obtain HEMOGENYX PHARMPLC's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine HEMOGENYX PHARMPLC's revenue streams: Identify HEMOGENYX PHARMPLC's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research HEMOGENYX PHARMPLC's industry and market trends, including the size of the market, growth rate, and competition.
- Establish HEMOGENYX PHARMPLC's growth potential: Evaluate HEMOGENYX PHARMPLC's management, business model, and growth potential.
- Determine HEMOGENYX PHARMPLC's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate HEMOGENYX PHARMPLC's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for HEMOGENYX Stock analysis
When running HEMOGENYX PHARMPLC's price analysis, check to measure HEMOGENYX PHARMPLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HEMOGENYX PHARMPLC is operating at the current time. Most of HEMOGENYX PHARMPLC's value examination focuses on studying past and present price action to predict the probability of HEMOGENYX PHARMPLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HEMOGENYX PHARMPLC's price. Additionally, you may evaluate how the addition of HEMOGENYX PHARMPLC to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |